HUMIRA

Type: Product
Name: HUMIRA
First reported 9 mins ago - Updated 9 mins ago - 1 reports

Celgene Announces Positive Data For Crohn’s Disease Drug

By Lori ClapperCelgene announced positive results Monday of its double blind multicenter Phase 2 trial of its Crohn’s Disease drug, GED-0301 . The company presented the data from the study, Mongersen, an Oral smad7 Antisense Oligonucleotide, in Active ... [Published Bioresearch Online - 9 mins ago]
First reported 23 hours ago - Updated 20 hours ago - 1 reports

Pharma feels force of US tax inversion law

The recent collapse of AbbVie’s proposed takeover of Shire is the first major pharmaceutical casualty of new US tax inversion legislation in a wake-up call for the pharma industry.According to Aparna Krishnan, an analyst with research and consulting firm ... [Published Pharma Field - 23 hours ago]
First reported Oct 22 2014 - Updated 23 hours ago - 2 reports

The Zacks Analyst Blog Highlights: AbbVie, Amgen, Regeneron, Pharmacyclics and Repros Therapeutics

For Immediate ReleaseChicago, IL – October 23, 2014 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks ... [Published Yahoo! Finance - Oct 23 2014]
First reported Oct 22 2014 - Updated Oct 22 2014 - 1 reports

Back to blogging.

I have always been terrible at writing in a journal, diary, etc. I wrote one post awhile back and just never been back to write another. I am trying to get back into it for several reasons. #1 I think my boyfriend can only listen to me talk about exercising, ... [Published Weight Watchers - Oct 22 2014]
First reported Oct 21 2014 - Updated Oct 21 2014 - 2 reports

AbbVie faces stumbling blocks after cutting cord on $55B Shire deal

AbbVie CEO Richard GonzalezDays after AbbVie ($ABBV) recommended that shareholders reject its $55 billion deal for Shire ($SHPG), the company officially cut the cord. And while Shire has big plans to succeed solo, AbbVie could face some stumbling blocks ... [Published FiercePharma - Oct 21 2014]
First reported Oct 21 2014 - Updated Oct 21 2014 - 1 reports

AbbVie announces positive phase 3 results of Humira for hidradenitis suppurativa treatment

AbbVie has announced results from its PIONEER II study demonstrating the effectiveness of Humira in reducing symptoms of moderate-to-severe hidradenitis suppurativa.The results of this study will contribute to worldwide regulatory filings to expand the ... [Published Orthopedics Today - Oct 21 2014]
First reported Oct 20 2014 - Updated Oct 21 2014 - 1 reports

Crohn's drug shows promise in mid-stage trial

Share this article:Celgene investigational Crohn's disease treatment GED-0301 (Mongersen) appear to surpass other drugs in terms of remission ratesMid-stage data for Celgene investigational Crohn's disease treatment GED-0301 (Mongersen) appear to surpass ... [Published Medical Marketing And Media - Oct 20 2014]
First reported Oct 20 2014 - Updated Oct 21 2014 - 4 reports

AbbVie CEO Gonzales loses Shire, but wins praise for gutsy move

NEW YORK - AbbVie Chief Executive Officer Richard Gonzalez for three months led the charge to buy Dublin drugmaker Shire for $55 billion, only to walk away from the deal last week, but analysts and fund managers said he deserves credit for trying and ... [Published Today Online - Oct 21 2014]
First reported Oct 20 2014 - Updated Oct 20 2014 - 1 reports

First Detailed Look at Celgene Crohn's Disease Pill Impresses

By: | 10/20/14 - 09:17 AM EDTThe first look at Celgene's ( CELG ) experimental Crohn's disease drug GED-0301 is impressive and explains why company executives have been so upbeat on the drug since acquiring it last spring for big bucks. As a pill, GED-031 ... [Published TheStreet.com - Oct 20 2014]
First reported Oct 20 2014 - Updated Oct 20 2014 - 1 reports

LG Life Sciences and Mochida sign agreement for treatment of autoimmune disease

LG Life Sciences Ltd., engaged in the pharmaceutical and fine chemical business, and Mochida Pharmaceutical Co., Ltd, have signed agreement for Humira Biosimilar, a treatment for the autoimmune disease, in Japan market. Mochida will have exclusive right ... [Published Individual.com - Oct 20 2014]
First reported Oct 18 2014 - Updated Oct 18 2014 - 1 reports

MannKind: 5 Potential Technosphere Applications

Summary MannKind's Technosphere technology allows drugs to be taken through an inhaler instead of through an injection. There are many injected treatments that could eventually be replaced by inhaled versions due to this technology. This article will ... [Published Seeking Alpha - Oct 18 2014]
Entities: Drugs, Lantus, Sanofi SA
First reported Oct 17 2014 - Updated Oct 17 2014 - 1 reports

AbbVie Still A Buy Despite Shire Fallout, Says Analyst

October 17, 2014By Riley McDermid , BioSpace.com Breaking News Sr. EditorEven if AbbVie 's ( ABBV ) doesn’t merge with Dublin-based Shire Pharmaceuticals 's ( SHPG ) and get the tax breaks the deal would have brought, it is still a solid buy for investors ... [Published BioSpace - Oct 17 2014]

Quotes

...the Street and we are impressed with the pace of Revlimid growth driven largely by volume,” wrote Joshua Schimmer , an analyst with Piper Jaffray . "While the quarter wasn't a blow-out, we are comfortable that LT prospects for CELG remain strong. CELG appears to be well positioned to deliver sustainable mid-20 percent EPS growth for the foreseeable future.”"
"We rate ABBVIE INC (ABBV) a HOLD. The primary factors that have impacted our rating are mixed -- some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. The company's strengths can be seen in multiple areas, such as its notable return on equity, revenue growth and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and weak operating cash flow."
"These payments, while not nefarious in every case, are a perfect symbol for the misaligned incentives in our health care system. While most health care stakeholders are working together to find ways to lower costs, drug makers remain focused on strategies to keep them inflated,” said Brendan Buck, spokesman for America s Health Insurance Plans."
"Other drugs that had failed in Phase III typically exhibited much more modest efficacy in Phase II," Yee wrote in a research note Tuesday. "So, in our view, the bottom line is this has a high chance of working in Phase III and should ultimately read out in 2016+ and could be another key growth driver for 2020, where we think upside long-term guidance could eventually be given."

More Content

All (340) | News (300) | Reports (0) | Blogs (39) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Celgene Announces Positive Data For Crohn’s Dis... [Published Bioresearch Online - 9 mins ago]
AbbVie head blasts Canada’s conflicting patent ... [Published Globe and Mail - 15 hours ago]
Celgene Beats The Street Again On Earnings And ... [Published BioSpace - 16 hours ago]
Celgene's (CELG) CEO Bob Hugin on Q3 2014 Resul... [Published Seeking Alpha - 17 hours ago]
Revlimid: Celgene Corporation's Gift That Keeps... [Published Motley Fool Discussion Boards - 20 hours ago]
Pharma feels force of US tax inversion law [Published Pharma Field - 23 hours ago]
The Zacks Analyst Blog Highlights: AbbVie, Amge... [Published Yahoo! Finance - Oct 23 2014]
Back to blogging. [Published Weight Watchers - Oct 22 2014]
Biotech Stock Roundup: AbbVie Calls off Shire A... [Published Nasdaq - Oct 22 2014]
Will This Price Target Increase Help AbbVie (AB... [Published The Street Latest - Oct 22 2014]
Public gets first look at health industry payme... [Published The Connecticut Mirror - Oct 22 2014]
Ben Goldacre: Pharma industry has destroyed its... [Published PharmaGossip - Oct 22 2014]
Celgene Rises 8% In Two Days On Crohn's Disease... [Published Yahoo! Finance - Oct 22 2014]
AbbVie scraps $52 billion Shire deal on U.S. ta... [Published San Francisco Chronicle - Oct 21 2014]
AbbVie announces positive phase 3 results of Hu... [Published Orthopedics Today - Oct 21 2014]
Celgene Reports More Good Crohn's Disease Data [Published Investor's Business Daily - Oct 21 2014]
AbbVie, Shire Call Off $51.7B Merger [Published Genetic Engineering News - Oct 21 2014]
AbbVie's $55B deal for Shire is officially dead... [Published FierceBiotech - Oct 21 2014]
AbbVie faces stumbling blocks after cutting cor... [Published FiercePharma - Oct 21 2014]
AbbVie Inc. (NYSE:ABBV) Board Approves A $5 Bil... [Published Live Trading News - Oct 21 2014]
3 Drugs Critical to Johnson & Johnson's Future [Published Motley Fool Discussion Boards - Oct 21 2014]
Market Overview:Global And China Monoclonal Ant... [Published MyNewsDesk - Oct 21 2014]
AbbVie ditches Shire as tax deal falters [Published Pharmafocus - Oct 21 2014]
AbbVie and Shire agree to end $52-billion deal [Published Los Angeles Times - Oct 21 2014]
AbbVie CEO Gonzales loses Shire, but wins prais... [Published Today Online - Oct 21 2014]
AbbVie scraps Shire deal, increases dividend [Published Boston Herald - Oct 21 2014]
AbbVie CEO Gonzales loses Shire, but wins prais... [Published Reuters - Oct 21 2014]
AbbVie scraps Shire deal, boosts dividend [Published USA Today - Oct 21 2014]
AbbVie Calls Off $55B Deal With Shire, Citing N... [Published Atlanta Journal And Constitution - Oct 21 2014]
Stock Update (NYSE:ABBV): AbbVie says $55 billi... [Published Jutia Group - Oct 21 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Ben Goldacre: Pharma industry has destroyed its... [Published PharmaGossip - Oct 22 2014]
Ben Goldacre [Scott Hurst/Flickr] EXCLUSIVE: The great tragedy for the pharmaceutical industry is that it keeps denying that it lobbies against transparency in clinical trials, says Ben Goldacre. Ben Goldacre is a British physician, academic and author ...
AbbVie reconsiders $54bn takeover of Shire: wha... [Published Guardian.co.uk - Business Blog - Oct 15 2014]
The news triggered a sell-off in UK pharmaceutical shares Chicago-based AbbVie has got cold feet over its planned $54bn (£34bn) takeover of British drugmaker Shire . The AbbVie board meets next Monday to reconsider the recommendation it made to shareholders ...
AbbVie Says To Reconsider Recommendation For Sh... [Published Clusterstock - Oct 15 2014]
<p><img style="float:right;" src="http://static5.businessinsider.com/image/543dd6705afbd374348b456c-450-300/abbvie-says-to-reconsider-recommendation-for-shire-acquisition.jpg" border="0" alt="A sign sits in front of Shire's manufacturing facility in Lexington, ...
AbbVie announces late-breaking results from Pha... [Published PBR - News - Oct 14 2014]
AbbVie announced new results from PIONEER II, a pivotal Phase III study, demonstrating the effect of HUMIRA (adalimumab) in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses ...
AbbVie Announces Late-Breaking Results from Pha... [Published PR Newswire: General Business - Oct 13 2014]
AMSTERDAM, Oct. 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced new results from PIONEER II, a pivotal Phase 3 study, demonstrating the effect of HUMIRA® (adalimumab)  in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis ...
1 2 3 4 5 6 7 8
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.